SCHEMBL5158468

SCHEMBL5158468

O=C(CC(=O)N1CCCC1)c1c[nH]c2ccccc12

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.65
KMT2A Q03164 4/20 0.65
POLB P06746 1/20 0.63
ALDH1A1 P00352 6/20 0.61
GAA P10253 2/20 0.61
MAPT P10636 2/20 0.61
TSHR P16473 2/20 0.61
ADAM17 P78536 1/20 0.54
CTNNB1 P35222 1/20 0.52
WNT3A P56704 1/20 0.52
CYP1A2 P05177 1/20 0.52
CYP2D6 P10635 1/20 0.52
CYP2C9 P11712 1/20 0.52
THPO P40225 1/20 0.52
MEN1 O00255 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
GPR84 Q9NQS5 1/20 0.51
PMP22 Q01453 1/20 0.51
HRH3 Q9Y5N1 1/20 0.51
NPC1 O15118 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5160513 0.99 KMT2A (0.67) RAB9AKMT2APOLBALDH1A1GAA
SCHEMBL289605 0.80 POLB (0.74) RAB9AKMT2APOLBALDH1A1GAA
SCHEMBL1413908 0.79 KMT2A (1.00) RAB9AKMT2APOLBALDH1A1MAPT
SCHEMBL6518029 0.77 ADAM17 (0.73) RAB9AKMT2AALDH1A1MAPTADAM17
SCHEMBL1851840 0.77 KMT2A (0.73) RAB9AKMT2AALDH1A1GAAMAPT
SCHEMBL3849918 0.77 POLB (1.00) RAB9AKMT2APOLBALDH1A1MAPT
SCHEMBL14832921 0.77 HAT1 (0.60)
SCHEMBL21530819 0.77 HAT1 (0.60)
SCHEMBL3122183 0.76 ALDH1A1 (0.67) RAB9AKMT2AALDH1A1ADAM17CTNNB1
SCHEMBL28415678 0.76 ADAM17 (0.62) KMT2AALDH1A1MAPTADAM17CTNNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293899-B2 Ketone transfer hydrogenation of stereoisomerically enriched 3-heteroaryl-3-oxocarboxylic esters by reducing 3-heteroaryl-3-hydroxycarboxylic esters in the presence of a ruthenium-containing catalyst, an amine and formic acid and/or formates LANXESS DEUTSCHLAND GMBH (DE) 2012-10-23 US disclosed
EP-1340746-B1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives SALTIGO GMBH (DE) 2007-02-28 EP disclosed
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives LANXESS DEUTSCHLAND GMBH (DE) 2003-12-04 US disclosed
EP-1340746-A1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives BAYER AG (DE) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives GRHPR, HPD, HAAO RAB9A 3428/4885KMT2A 1666/4885POLB 2040/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.